Ainos (NASDAQ:AIMD) Major Shareholder Sells $99,820.00 in Stock

Ainos, Inc. (NASDAQ:AIMD) major shareholder Carbon Nano Technology Taiwan sold 46,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 28th. The shares were sold at an average price of $2.17, for a total transaction of $99,820.00. Following the completion of the transaction, the insider owned 989,925 shares of the company’s stock, valued at $2,148,137.25. This trade represents a 4.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Carbon Nano Technology Taiwan also recently made the following trade(s):

• On Friday, January 9th, Carbon Nano Technology Taiwan sold 431 shares of Ainos stock. The stock was sold at an average price of $1.86, for a total transaction of $801.66.
• On Thursday, January 8th, Carbon Nano Technology Taiwan sold 850 shares of Ainos stock. The stock was sold at an average price of $1.80, for a total transaction of $1,530.00.

Ainos Stock Up 10.3%

NASDAQ AIMD traded up $0.22 on Thursday, reaching $2.35. The company had a trading volume of 1,187,513 shares, compared to its average volume of 1,786,459. The company’s fifty day moving average is $1.99 and its 200-day moving average is $2.85. The firm has a market capitalization of $11.30 million, a price-to-earnings ratio of -0.59 and a beta of 2.45. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.67 and a current ratio of 2.96. Ainos, Inc. has a 1-year low of $1.61 and a 1-year high of $4.50.

Ainos (NASDAQ:AIMD) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.64) earnings per share (EPS) for the quarter. The business had revenue of $0.00 million during the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ainos in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Hedge Funds Weigh In On Ainos

A hedge fund recently bought a new stake in Ainos stock. Two Sigma Investments LP purchased a new stake in Ainos, Inc. (NASDAQ:AIMD) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 23,008 shares of the company’s stock, valued at approximately $80,000. Two Sigma Investments LP owned about 0.48% of Ainos at the end of the most recent reporting period.

About Ainos

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.